Exact Mass: 481.1636712
Exact Mass Matches: 481.1636712
Found 118 metabolites which its exact mass value is equals to given mass value 481.1636712
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Rosuvastatin
C22H28FN3O6S (481.16827600000005)
Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Rosuvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
(3R,5R)-7-[4-(4-Fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid
C22H28FN3O6S (481.16827600000005)
Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)-, (2S)-
C23H26F3N3O3S (481.1646882000001)
2,3-di(acetyloxy)-4-anilino-1-[1,2-di(acetyloxy)ethyl]-4-oxobutyl acetate
C22H27NO11 (481.15840320000007)
Rosuvastatin
C22H28FN3O6S (481.16827600000005)
C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; EAWAG_UCHEM_ID 2802
Cys Cys Glu Lys
Cys Cys Lys Glu
Cys Glu Cys Lys
Cys Glu Lys Cys
Cys Lys Cys Glu
Cys Lys Glu Cys
Cys Met Gln Thr
Cys Met Thr Gln
Cys Gln Met Thr
Cys Gln Thr Met
Cys Ser Ser Trp
C20H27N5O7S (481.16311120000006)
Cys Ser Trp Ser
C20H27N5O7S (481.16311120000006)
Cys Thr Met Gln
Cys Thr Gln Met
Cys Trp Ser Ser
C20H27N5O7S (481.16311120000006)
Glu Cys Cys Lys
Glu Cys Lys Cys
Glu Lys Cys Cys
Lys Cys Cys Glu
Lys Cys Glu Cys
Lys Glu Cys Cys
Met Cys Gln Thr
Met Cys Thr Gln
Met Met Asn Ser
Met Met Ser Asn
Met Asn Met Ser
Met Asn Ser Met
Met Gln Cys Thr
Met Gln Thr Cys
Met Ser Met Asn
Met Ser Asn Met
Met Thr Cys Gln
Met Thr Gln Cys
Asn Met Met Ser
Asn Met Ser Met
Asn Ser Met Met
Gln Cys Met Thr
Gln Cys Thr Met
Gln Met Cys Thr
Gln Met Thr Cys
Gln Thr Cys Met
Gln Thr Met Cys
Ser Cys Ser Trp
C20H27N5O7S (481.16311120000006)
Ser Cys Trp Ser
C20H27N5O7S (481.16311120000006)
Ser Met Met Asn
Ser Met Asn Met
Ser Asn Met Met
Ser Ser Cys Trp
C20H27N5O7S (481.16311120000006)
Ser Ser Trp Cys
C20H27N5O7S (481.16311120000006)
Ser Trp Cys Ser
C20H27N5O7S (481.16311120000006)
Ser Trp Ser Cys
C20H27N5O7S (481.16311120000006)
Thr Cys Met Gln
Thr Cys Gln Met
Thr Met Cys Gln
Thr Met Gln Cys
Thr Gln Cys Met
Thr Gln Met Cys
Trp Cys Ser Ser
C20H27N5O7S (481.16311120000006)
Trp Ser Cys Ser
C20H27N5O7S (481.16311120000006)
Trp Ser Ser Cys
C20H27N5O7S (481.16311120000006)
Bifeprunox Mesylate
C25H27N3O5S (481.1671332000001)
C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Bifeprunox mesylate is a potent dopamine D2-like and 5-HT1A receptor partial agonist with pKis of 7.19 and 8.83 for cortex 5-HT1A and striatum D2, and a pEC50 of 6.37 for hippocampus 5-HT1A, respectively. Bifeprunox mesylate is an antipsychotic for the research of schizophrenia[1][2].
(E)-7-(4-(4-Fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid
C22H28FN3O6S (481.16827600000005)
(3r,5r,e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid
C22H28FN3O6S (481.16827600000005)
Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)-, (2S)-
C23H26F3N3O3S (481.1646882000001)
N-[2-[(2-furanylmethylamino)-oxomethyl]phenyl]-4-methyl-3-(1-piperidinylsulfonyl)benzamide
C25H27N3O5S (481.1671332000001)
2-[(4-ethoxyphenyl)sulfonylamino]-N-[2-(4-morpholinyl)phenyl]benzamide
C25H27N3O5S (481.1671332000001)
N-[[(2S,3R)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
C22H32BrN3O4 (481.15760520000003)
N-[[(2R,3R)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
C22H32BrN3O4 (481.15760520000003)
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-[[4-[3-(dimethylamino)propyl]-5-pyridin-4-yl-1,2,4-triazol-3-yl]thio]acetamide
(1S,9R,10R,11R)-N-[(3,5-difluorophenyl)methyl]-10-(hydroxymethyl)-6-oxo-12-(pyrazine-2-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
N-[[(2S,3R)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2R,3S)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[(3-fluorophenyl)methyl]-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C23H23F4N3O4 (481.16246060000003)
N-[(3-fluorophenyl)methyl]-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C23H23F4N3O4 (481.16246060000003)
N-[(3-fluorophenyl)methyl]-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C23H23F4N3O4 (481.16246060000003)
1-[(2R,3S,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
C22H28FN3O6S (481.16827600000005)
1-[(2R,3R,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
C22H28FN3O6S (481.16827600000005)
1-[(2S,3S,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
C22H28FN3O6S (481.16827600000005)
(1R,9S,10S,11S)-N-[(3,5-difluorophenyl)methyl]-10-(hydroxymethyl)-6-oxo-12-(pyrazine-2-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
N-[[(2R,3S)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2R,3R)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2S,3R)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2S,3S)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2S,3S)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
C22H32BrN3O4 (481.15760520000003)
N-[[(2R,3R)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
C22H32BrN3O4 (481.15760520000003)
N-[[(2R,3S)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
C22H32BrN3O4 (481.15760520000003)
N-[[(2R,3S)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
C22H32BrN3O4 (481.15760520000003)
N-[[(2S,3R)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
C22H32BrN3O4 (481.15760520000003)
N-[[(2S,3S)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
C22H32BrN3O4 (481.15760520000003)
N-[(3-fluorophenyl)methyl]-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C23H23F4N3O4 (481.16246060000003)
N-[(3-fluorophenyl)methyl]-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C23H23F4N3O4 (481.16246060000003)
N-[(3-fluorophenyl)methyl]-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C23H23F4N3O4 (481.16246060000003)
N-[(3-fluorophenyl)methyl]-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C23H23F4N3O4 (481.16246060000003)
N-[(3-fluorophenyl)methyl]-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C23H23F4N3O4 (481.16246060000003)
1-[(2S,3R,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
C22H28FN3O6S (481.16827600000005)
1-[(2S,3R,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
C22H28FN3O6S (481.16827600000005)
1-[(2S,3S,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
C22H28FN3O6S (481.16827600000005)
1-[(2R,3S,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
C22H28FN3O6S (481.16827600000005)
1-[(2R,3R,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
C22H28FN3O6S (481.16827600000005)
GSK598809
GSK598809 is a potent and selective dopamine D3 Receptor (DRD3) antagonist, with a pKi of 8.9.
4-(hydroxymethyl)-5,6-dimethoxy-3-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-4,8(13),9,11,14(28),15(19),17,20(27),21(26),22,24-undecaen-18-ol
C28H23N3O5 (481.16376280000003)
(2r,6s)-4-(hydroxymethyl)-5,6-dimethoxy-3-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-4,8(13),9,11,14(28),15(19),17,20(27),21(26),22,24-undecaen-18-ol
C28H23N3O5 (481.16376280000003)
(10s)-10-{[(2s,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-8-ethyl-1,6,11-trihydroxy-9,10-dihydrotetracene-5,12-dione
C26H27NO8 (481.17365820000003)
10-[(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy]-8-ethyl-1,6,11-trihydroxy-9,10-dihydrotetracene-5,12-dione
C26H27NO8 (481.17365820000003)